# TUSC2 Gene: Structure, Function, and Clinical Significance ## Key Takeaways - TUSC2 (FUS1) is a bona fide tumor suppressor gene located at chromosome 3p21.3, a region frequently deleted in lung cancers and other solid malignancies. Its loss, often through promoter hypermethylation or mRNA instability, is observed in 80-90% of NSCLC, SCLC, mesotheliomas, breast cancers, and glioblastomas. - The TUSC2 protein, a 110-amino-acid mitochondrial-resident molecule, acts as a pleiotropic regulator of apoptosis, cellular metabolism, calcium homeostasis, immune surveillance, and kinase signaling, including direct inhibition of EGFR, ALK, and mTOR pathways. - Inactivation of TUSC2 is primarily mediated by epigenetic silencing (promoter hypermethylation) and post-transcriptional mechanisms (mRNA instability, microRNA targeting, and NEDD4-mediated proteasomal degradation), rather than solely through somatic mutations. - Quaratusugene ozeplasmid (Reqorsa™), a systemic TUSC2 gene therapy delivered via cationic lipid nanoparticles, has demonstrated single-agent activity and synergy with targeted inhibitors (osimertinib, sotorasib), immunotherapies (anti-PD-1/PD-L1), and chemotherapy in preclinical models and early-phase clinical trials. - TUSC2's therapeutic potential is underscored by its ability to re-sensitize resistant tumors to standard-of-care agents, functioning as a paradigm for "tumor suppressor gene therapy" by restoring a lost gatekeeper protein. - Biomarkers such as TROP2 expression and PTEN loss have been identified as potential indicators of primary resistance to TUSC2 gene therapy in NSCLC, guiding patient selection for combination strategies. --- ## Executive Summary & Key Metadata TUSC2 (TUmor Suppressor Candidate 2), also widely known as FUS1 (FUSion 1), is a bona fide tumor suppressor gene originally identified within the human chromosome 3p21.3 critical deletion region, a locus lost in the majority of lung cancers and a substantial fraction of other solid malignancies [1, 2]. The gene product is a 110-amino-acid, 13-kDa mitochondrial-resident protein that functions as a pleiotropic regulator of apoptosis, cellular metabolism, calcium homeostasis, immune surveillance, and kinase signaling [1, 3, 4, 5]. TUSC2 expression is lost or severely reduced in approximately 80–90% of non-small cell lung cancers (NSCLC), small cell lung cancers (SCLC), mesotheliomas, breast cancers, and glioblastomas, frequently through mechanisms independent of homozygous deletion, including promoter hypermethylation, mRNA instability, and proteasomal degradation [1, 6, 7, 8]. The clinical relevance of TUSC2 has been amplified by the development of quaratusugene ozeplasmid (Reqorsa™), a systemic gene therapy consisting of a TUSC2-expressing plasmid encapsulated in cationic lipid nanoparticles. This agent has demonstrated single-agent activity and synergy with targeted inhibitors (osimertinib, sotorasib), immunotherapies (anti-PD-1, anti-PD-L1), and chemotherapy in extensive preclinical models and early-phase clinical trials [1, 2, 3, 9, 10, 11, 12, 13, 14]. TUSC2 is thus a paradigm for the "tumor suppressor gene therapy" concept, where restoration of a lost gatekeeper protein re-sensitizes resistant tumors to standard-of-care agents. | **Attribute** | **Value** | |---|---| | **HGNC Symbol** | TUSC2 | | **Aliases** | FUS1, PAP, PDAP2, C3orf11 | | **UniProt Accession** | O75896 | | **Representative PDB ID** | true (homology models; experimental structure pending) | | **Chromosomal Locus** | 3p21.3 | | **NCBI Gene ID** | 11334 | | **Ensembl ID** | ENSG00000115523 | | **Primary Molecular Function** | Tumor suppressor; apoptosis promoter; mitochondrial Ca²⁺ regulator; kinase inhibitor; immune modulator | | **Disease & Pathology Associations** | NSCLC, SCLC, mesothelioma, breast cancer, glioblastoma, thyroid cancer, ovarian cancer, bladder cancer, nasopharyngeal carcinoma, head-and-neck cancer, Alzheimer's disease, hearing loss, focal segmental glomerulosclerosis | | **Therapeutic Modality** | Quaratusugene ozeplasmid (Reqorsa™) gene therapy; combination with TKIs, checkpoint inhibitors, chemotherapy | --- ## 1. Genomic Locus, Chromosomal Organization & Isoforms ### 1.1 Chromosomal Localization and Genomic Context The TUSC2 gene is located on the short arm of chromosome 3 at band 3p21.3, a genomic interval of approximately 630 kb that is homozygously deleted in nearly 100% of SCLC cell lines and a large proportion of NSCLC tumors [1, 2]. This region harbors a dense cluster of tumor suppressor genes, including RASSF1, BLU (ZMYND10), NPRL2, and SEMA3B, and is considered one of the most frequently deleted chromosomal regions in human cancer [1, 4]. The TUSC2 locus spans approximately 5.5 kb of genomic DNA on the minus strand (NCBI GRCh38: chr3:50,317,958–50,323,457). The gene comprises three exons and two introns, with the entire coding sequence contained within exon 2 [1, 6]. The 3p21.3 region is characterized by a high density of Alu repeats and segmental duplications, which predispose to non-allelic homologous recombination and consequent chromosomal deletions during tumorigenesis [1]. The minimal critical deleted region in lung cancer includes TUSC2, and loss of heterozygosity (LOH) at 3p21.3 is among the earliest genetic events in the pathogenesis of lung cancer, detectable in pre-neoplastic bronchial lesions [2]. ### 1.2 Promoter Architecture and Transcriptional Regulation The TUSC2 promoter region lacks a canonical TATA box but contains multiple GC-rich elements and putative binding sites for the transcription factors Sp1, AP-1, and E2F [1]. The promoter is embedded within a CpG island that spans the transcription start site and extends into exon 1. Hypermethylation of this CpG island has been documented in breast cancer cell lines and primary tumors, correlating with transcriptional silencing [4]. In head-and-neck squamous cell carcinoma, epigenetic silencing of the 3p21.3 cluster, including TUSC2, is mediated by promoter hypermethylation and histone deacetylation [5, 6]. Transcriptional regulation of TUSC2 is also influenced by the pseudogene TUSC2P. The TUSC2P pseudogene, located on chromosome 3q27, produces a long non-coding RNA that shares high sequence homology with the TUSC2 3' untranslated region (UTR). TUSC2P acts as a competitive endogenous RNA (ceRNA) or "miRNA sponge," sequestering microRNAs that would otherwise target TUSC2 mRNA, thereby derepressing TUSC2 expression [7, 8]. This regulatory axis is particularly active in esophageal squamous cell carcinoma, where TUSC2P expression correlates with TUSC2 protein levels and favorable prognosis [7]. ### 1.3 Post-Transcriptional Regulation and mRNA Stability The TUSC2 mRNA is subject to complex post-transcriptional regulation mediated by its 5' and 3' UTRs. The 5' UTR contains an upstream open reading frame (uORF) that represses translation under basal conditions, while the 3' UTR harbors multiple AU-rich elements (AREs) and microRNA binding sites that modulate mRNA stability [6]. In lung cancer cell lines, TUSC2 mRNA is often detectable by Northern blot, yet the protein is absent, indicating a dominant post-transcriptional block to expression [6]. This block is mediated by the 3' UTR, which promotes mRNA decay through a mechanism involving microRNA-directed uridylation and exonucleolytic degradation [6, 9]. Several microRNAs have been validated to directly target the TUSC2 3' UTR and repress its expression: - **miR-197**: Downregulates TUSC2 in glioblastoma, contributing to tumor progression [10]. - **miR-663 / miR-663b**: Represses TUSC2 in ovarian cancer, nasopharyngeal carcinoma, and bladder cancer, promoting proliferation, migration, and invasion [11, 12, 13]. - **miR-138**: Targets TUSC2 in triple-negative breast cancer, where its overexpression correlates with poor prognosis [1, 14]. - **miR-378a-5p**: Downregulates TUSC2 in NSCLC; sea cucumber peptides inhibit malignancy by upregulating miR-378a-5p, which in turn targets TUSC2 [2]. - **miR-19a**: Identified as a direct regulator of TUSC2 in lung cancer progression [3]. ### 1.4 Alternative Splicing and Isoforms The TUSC2 gene produces a single major protein-coding transcript of approximately 1.3 kb, encoding the 110-amino-acid protein. No functionally validated alternative splicing isoforms have been described. However, the TUSC2P pseudogene produces a non-coding transcript that is structurally similar to TUSC2 mRNA but lacks protein-coding capacity [8]. The absence of splice variants suggests that TUSC2 function is tightly controlled at the transcriptional and post-transcriptional levels rather than through isoform diversity. --- ## 2. 3D Protein Domain Architecture & Structural Biology ### 2.1 Primary Sequence and Domain Organization The TUSC2 protein is a small, 110-amino-acid polypeptide (molecular weight ~13 kDa) with a primary sequence that is highly conserved across mammals [1]. The protein lacks canonical enzymatic domains, DNA-binding motifs, or transmembrane helices, indicating that its functions are mediated through protein-protein interactions and post-translational modifications [1, 4]. The domain architecture can be delineated as follows: - **N-terminal region (residues 1–30)**: Contains a mitochondrial targeting sequence (MTS) that directs the protein to the mitochondrial inner membrane space. This region is rich in basic and hydrophobic residues, characteristic of cleavable presequences [4, 5]. - **Central region (residues 31–80)**: Contains a putative calcium-binding EF-hand-like motif and a phosphorylation site at Ser⁶⁶. This region mediates interactions with the mitochondrial calcium uniporter (MCU) complex and the pro-apoptotic protein BAX [4, 5]. - **C-terminal region (residues 81–110)**: Contains a polybasic stretch that facilitates interaction with negatively charged phospholipids and the adaptor protein 14-3-3. This region also harbors a nuclear export signal (NES)-like motif [1]. ### 2.2 Secondary and Tertiary Structure Circular dichroism and computational predictions indicate that TUSC2 is predominantly α-helical, with approximately 60% of residues adopting helical conformation. The protein folds into a globular domain stabilized by hydrophobic core interactions and a single disulfide bond between Cys²⁵ and Cys⁸⁵ [1]. The EF-hand-like motif in the central region is predicted to coordinate a single Ca²⁺ ion, although the binding affinity is lower than that of canonical EF-hand proteins, suggesting a regulatory rather than buffering role [4]. The C-terminal polybasic region forms an amphipathic helix that can insert into the inner mitochondrial membrane, anchoring TUSC2 to the cristae. This membrane association is critical for TUSC2's interaction with the MCU complex and for its pro-apoptotic function [4, 5]. ### 2.3 Post-Translational Modifications TUSC2 is subject to several post-translational modifications that modulate its stability and function: - **Phosphorylation at Ser⁶⁶**: Mediated by protein kinase A (PKA) or AKT, this modification enhances TUSC2's interaction with 14-3-3 proteins, promoting its cytoplasmic retention and inhibiting its mitochondrial translocation [1]. - **Polyubiquitination**: TUSC2 is a substrate for the E3 ubiquitin ligase NEDD4. NEDD4-mediated polyubiquitination targets TUSC2 for proteasomal degradation, and NEDD4 is overexpressed in glioblastoma, leading to loss of TUSC2 protein despite normal mRNA levels [7]. This mechanism explains the discordance between TUSC2 mRNA and protein expression observed in multiple cancer types [4, 7]. - **Acetylation**: Lysine acetylation at K⁴⁹ has been detected by mass spectrometry, though the functional consequences remain to be fully characterized [1]. ### 2.4 Structural Insights from Homology Models No high-resolution experimental structure of human TUSC2 has been deposited in the Protein Data Bank (PDB). However, homology models based on the structure of the yeast mitochondrial protein Mrs2 and the bacterial EF-hand protein calerythrin provide a plausible structural framework. These models predict a four-helix bundle with a calcium-binding loop between helices 2 and 3, consistent with the biophysical data [1, 4]. The absence of an experimental structure is a limitation for structure-based drug design, but the small size and high stability of TUSC2 make it amenable to NMR-based structure determination. > **[Interactive 3D Protein Visualizer: Load TUSC2 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O75896)** > > Explore the predicted 3D architecture of TUSC2, including the N-terminal mitochondrial targeting sequence, the central calcium-binding EF-hand motif, and the C-terminal membrane-anchoring helix. The visualizer integrates AlphaFold predictions, post-translational modification sites, and known pathogenic mutation positions. --- ## 3. Cellular Signaling Pathways & Molecular Function ### 3.1 Apoptosis and Mitochondrial Signaling TUSC2 is a potent pro-apoptotic protein that functions primarily through the intrinsic (mitochondrial) apoptotic pathway. Upon cellular stress, TUSC2 translocates to the mitochondria, where it interacts with the mitochondrial calcium uniporter (MCU) complex and the pro-apoptotic protein BAX [4, 5]. TUSC2 promotes mitochondrial Ca²⁺ uptake, leading to mitochondrial permeability transition pore (mPTP) opening, release of cytochrome c, and activation of the caspase cascade [4, 5]. This mechanism is selective for cancer cells; normal cells are protected by higher expression of anti-apoptotic BCL-2 family members and more efficient Ca²⁺ buffering [13]. TUSC2 also upregulates the expression of SMAC/DIABLO, a mitochondrial protein that neutralizes inhibitor of apoptosis proteins (IAPs), thereby amplifying the apoptotic signal [5]. In thyroid cancer cells, TUSC2 re-expression induces apoptosis through SMAC/DIABLO upregulation, and this effect is dependent on the mitochondrial localization of TUSC2 [5]. ### 3.2 Kinase Inhibition and mTOR Signaling TUSC2 functions as a broad-spectrum kinase inhibitor, directly binding to and inhibiting the activity of multiple receptor tyrosine kinases (RTKs) and downstream signaling kinases. TUSC2 has been shown to inhibit: - **EGFR** and its downstream effectors AKT and ERK [6, 11]. - **ALK** fusion proteins (EML4-ALK) in NSCLC [7, 8]. - **PDGFR** and **VEGFR** signaling [1]. - **mTOR** and its downstream targets p70S6K and 4E-BP1 [9]. The inhibition of mTOR signaling by TUSC2 is particularly significant. TUSC2 downregulates mTOR activity, leading to reduced phosphorylation of p70S6K and S6 ribosomal protein [9]. This mTOR inhibition is mechanistically linked to TUSC2-mediated downregulation of PD-L1 expression, as both TUSC2 overexpression and rapamycin treatment produce similar effects on PD-L1 levels [9]. The TUSC2-mTOR-PD-L1 axis provides a direct link between tumor suppressor function and immune evasion. ### 3.3 Regulation of Energy Metabolism TUSC2 is a critical regulator of cellular energy metabolism. In lung cancer cells, TUSC2 suppresses glycolysis and oxidative phosphorylation, reducing ATP production and promoting a quiescent, non-proliferative state [3]. This metabolic suppression is mediated by TUSC2's inhibition of the PI3K/AKT/mTOR axis and its direct effects on mitochondrial electron transport chain complexes [3, 10]. In contrast, in normal bronchial epithelial cells, TUSC2 enhances mitochondrial function and ATP production, supporting cellular homeostasis [3]. This differential effect on cancer versus normal cells underscores the therapeutic window of TUSC2 gene therapy. In the Fus1/Tusc2 knockout mouse model, loss of TUSC2 leads to mitochondrial dysfunction, increased oxidative stress, and hyperactivation of the mTOR pathway [10, 11]. These mice exhibit premature hearing loss, which can be rescued by pharmacological modulation of energy metabolism, including treatment with metformin and the mTOR inhibitor rapamycin [10]. TUSC2 knockout mice also develop a brain pro-inflammatory microenvironment and early spatial memory impairment, recapitulating features of sporadic Alzheimer's disease [5, 11]. ### 3.4 Calcium Homeostasis and Immune Function TUSC2 is a mitochondrial-resident protein that regulates cellular Ca²⁺ homeostasis. By modulating MCU activity, TUSC2 controls the amplitude and kinetics of mitochondrial Ca²⁺ uptake, which in turn influences cytosolic Ca²⁺ oscillations, NFAT signaling, and T-cell activation [4, 5]. TUSC2-deficient T cells exhibit impaired Ca²⁺ flux and reduced cytokine production, contributing to the immuno-inflammatory phenotype of Tusc2 knockout mice [4, 12]. TUSC2 also modulates the function of natural killer (NK) cells. Restoring TUSC2 function in TUSC2-deficient tumors enhances NK cell cytotoxicity and antitumor immunity [13]. This effect is mediated by TUSC2-induced changes in the tumor microenvironment, including reduced PD-L1 expression and increased secretion of pro-inflammatory cytokines [13, 14]. ### 3.5 Protein-Protein Interaction Network The TUSC2 interactome includes both mitochondrial and cytosolic partners. Key validated interactions include: - **BAX**: Direct interaction promoting mitochondrial outer membrane permeabilization [4]. - **MCU**: Regulation of mitochondrial Ca²⁺ uptake [4, 5]. - **14-3-3 proteins**: Phosphorylation-dependent binding that regulates subcellular localization [1]. - **NEDD4**: E3 ubiquitin ligase that targets TUSC2 for degradation [7]. - **AKT**: Direct inhibition of kinase activity [1]. - **mTOR**: Downstream effector of TUSC2 signaling [9]. STRING and BioGRID databases list over 50 predicted and validated interaction partners, reflecting the pleiotropic nature of TUSC2 function. ### 3.6 Signaling Pathway Diagram ```mermaid sequenceDiagram participant TUSC2 as "TUSC2 Protein" participant MCU as "Mitochondrial Ca²⁺ Uniporter" participant BAX as "Pro-apoptotic BAX" participant mTOR as "mTOR Complex" participant PD-L1 as PD-L1 Expression participant NK as "NK Cell" participant TUMOR as "Tumor Cell" TUSC2->>MCU: Binds and activates MCU->>BAX: Promotes mPTP opening BAX->>TUMOR: Cytochrome c release → Apoptosis TUSC2->>mTOR: Inhibits kinase activity mTOR->>PD-L1: Downregulates expression PD-L1->>NK: Reduced immune evasion NK->>TUMOR: Enhanced cytotoxicity TUSC2->>TUMOR: Direct kinase inhibition (EGFR, ALK, AKT) ``` --- ## 4. Pathogenic Hotspot Mutations & Clinical Differentials ### 4.1 Somatic Mutations in Cancer TUSC2 is not a classical mutation hotspot gene; rather, its inactivation in cancer is predominantly achieved through epigenetic silencing, mRNA instability, and protein degradation [1, 6, 7]. However, somatic mutations have been identified in various cancer types, and their functional significance is an area of active investigation. The COSMIC database lists over 100 somatic mutations in TUSC2 across multiple cancer types, including: - **Missense mutations**: Predominantly located in the central and C-terminal regions. Notable examples include: - **R62W**: Located within the EF-hand-like motif; predicted to disrupt Ca²⁺ binding. - **L75P**: Located in the hydrophobic core; predicted to destabilize the protein fold. - **G95R**: Located in the C-terminal polybasic region; predicted to impair membrane association. - **Nonsense mutations**: Rare, but when present, result in truncation of the C-terminal region and loss of membrane anchoring. - **Frameshift mutations**: Occur in microsatellite-unstable tumors, leading to complete loss of protein function. The clinical significance of these mutations is uncertain, as TUSC2 loss is more commonly achieved through non-mutational mechanisms. However, the presence of truncating mutations in a subset of tumors suggests that TUSC2 can act as a classical "two-hit" tumor suppressor in some contexts. ### 4.2 Germline Variants and Polymorphisms Several germline single-nucleotide polymorphisms (SNPs) in TUSC2 have been identified, though none have been definitively associated with cancer predisposition. The most studied variant is rs3862720 (c.327C>T, p.Ser109=), a synonymous variant that has been investigated as a potential biomarker in lung cancer, but results have been inconclusive. ### 4.3 Epigenetic Inactivation Promoter hypermethylation of TUSC2 is a major mechanism of inactivation in: - **Breast cancer**: Hypermethylation of the 3p21.3 cluster, including TUSC2, is observed in breast cancer cell lines and primary tumors [4]. - **Head-and-neck cancer**: Epigenetic silencing of TUSC2 and neighboring genes is common [5, 6]. - **Mesothelioma**: TUSC2 deficiency in mesothelioma is associated with promoter methylation and histone modifications [8]. ### 4.4 Protein-Level Inactivation NEDD4-mediated ubiquitination and proteasomal degradation of TUSC2 is a critical mechanism of protein loss in glioblastoma [7]. In GBM, NEDD4 is overexpressed, leading to reduced TUSC2 protein despite normal mRNA levels. This protein-level regulation explains the poor correlation between TUSC2 mRNA and protein expression observed in multiple cancer types [4, 7]. ### 4.5 Clinical Differential and Prognostic Significance Loss of TUSC2 expression is associated with worse overall survival in lung cancer, breast cancer, and glioblastoma [1, 2, 4]. In breast cancer, TUSC2 expression is reduced in a significant proportion of tumors, and its loss correlates with aggressive clinicopathological features [2, 3]. In glioblastoma, TUSC2 protein expression is reduced or lost in the majority of tumors, and restoration of TUSC2 suppresses glioma growth in preclinical models [4, 7]. --- ## 5. Host-Pathogen & Viral Interactions ### 5.1 Human Papillomavirus (HPV) and Cervical Cancer TUSC2 is located on chromosome 3p21.3, a region frequently deleted in HPV-independent cervical cancers. In juvenile cervical clear cell adenocarcinoma, a rare HPV-independent malignancy, genetic alterations in the 3p21.3 region, including TUSC2, have been identified [5]. The loss of TUSC2 in these tumors may contribute to their aggressive phenotype, though the precise role of TUSC2 in HPV-related carcinogenesis remains to be fully defined. ### 5.2 Viral Oncoproteins and TUSC2 Degradation While no direct interaction between viral oncoproteins and TUSC2 has been reported, the functional convergence of viral oncogene signaling and TUSC2 loss is evident. For example, HPV E6/E7 oncoproteins activate the PI3K/AKT/mTOR pathway, which is also hyperactivated when TUSC2 is lost [9]. Similarly, the Epstein-Barr virus (EBV) latent membrane protein 1 (LMP1) upregulates miR-663b, which targets TUSC2, providing a mechanistic link between EBV infection and TUSC2 downregulation in nasopharyngeal carcinoma [12]. ### 5.3 Immune Evasion and TUSC2 TUSC2 modulates the immune microenvironment through multiple mechanisms: - **PD-L1 downregulation**: TUSC2 inhibits mTOR, leading to reduced PD-L1 expression and enhanced T-cell and NK-cell antitumor activity [9, 13, 14]. - **NK cell activation**: TUSC2 restoration enhances NK cell infiltration and cytotoxicity in syngeneic mouse models [13, 14]. - **Innate immune activation**: TUSC2 gene therapy activates innate immune pathways, including STING and type I interferon signaling, contributing to its immunogene therapy effects [6, 12]. The ability of TUSC2 to enhance checkpoint blockade immunotherapy is a key rationale for its clinical development. In humanized mouse models, TUSC2 gene therapy synergizes with anti-PD-1 and anti-PD-L1 antibodies, leading to enhanced tumor regression and improved survival [6, 7, 8, 12, 14]. --- ## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors ### 6.1 Quaratusugene Ozeplasmid (Reqorsa™) Quaratusugene ozeplasmid (Reqorsa™, formerly Oncoprex™) is the lead TUSC2-based therapeutic. It consists of a plasmid DNA encoding the full-length human TUSC2 cDNA, encapsulated in cationic lipid nanoparticles (DOTAP:cholesterol) [9, 13]. The nanoparticles are designed to exploit the negative charge of cancer cell membranes, facilitating selective uptake by tumor cells [9]. **Clinical Development:** - **Phase I trial (NCT00059605)**: Systemically administered TUSC2-nanoparticles demonstrated successful gene transfer, transgene expression, and evidence of apoptosis in tumor biopsies from patients with advanced lung cancer. The treatment was well-tolerated, with no dose-limiting toxicities [10, 13]. - **ACCLAIM-1 trial**: A phase 1/2 study evaluating quaratusugene ozeplasmid in combination with osimertinib in patients with advanced EGFR-mutant NSCLC. The recommended phase 2 dose (RP2D) was determined, and the combination demonstrated promising activity, including responses in patients with acquired resistance to osimertinib [1, 2, 3]. - **ACCLAIM-2 trial**: A phase 1/2 study evaluating quaratusugene ozeplasmid in combination with atezolizumab maintenance therapy in extensive-stage SCLC [14]. - **Sotorasib combination**: Preclinical studies demonstrate that TUSC2 gene therapy overcomes acquired resistance to sotorasib in KRASG12C-mutant NSCLC, providing a rationale for clinical evaluation [9, 10]. ### 6.2 Combination Strategies TUSC2 gene therapy has demonstrated synergy with multiple agents: - **Osimertinib (EGFR-TKI)**: TUSC2 overcomes osimertinib resistance in EGFR-mutant NSCLC by inhibiting downstream signaling pathways (AKT, ERK, mTOR) and inducing apoptosis [1, 2, 11]. - **Sotorasib (KRASG12C inhibitor)**: TUSC2 overcomes sotorasib acquired resistance through inhibition of bypass signaling pathways [9, 10]. - **MK2206 (AKT inhibitor)**: TUSC2 re-expression sensitizes NSCLC cells to MK2206 in an LKB1-dependent manner [1]. - **Erlotinib (EGFR-TKI)**: TUSC2 restores erlotinib sensitivity in EGFR wild-type NSCLC cells [6, 11]. - **Auranofin (thioredoxin reductase inhibitor)**: TUSC2-erlotinib combination induces vulnerabilities to auranofin in EGFR wild-type NSCLC [11]. - **Carboplatin + pembrolizumab**: TUSC2 enhances the efficacy of chemo-immunotherapy in KRAS/LKB1-mutant NSCLC [12]. - **Anti-PD-1/PD-L1**: TUSC2 synergizes with checkpoint inhibitors through enhanced NK cell infiltration and reduced PD-L1 expression [8, 14]. ### 6.3 Predictive Biomarkers Biomarkers of primary resistance to TUSC2 gene therapy include: - **TROP2**: High TROP2 expression is associated with primary resistance to TUSC2 gene therapy in NSCLC [12]. - **PTEN loss**: Loss of PTEN is associated with primary resistance to TUSC2 gene therapy [12]. These biomarkers may guide patient selection for TUSC2-based therapies. ### 6.4 Small-Molecule Modulators of TUSC2 Expression Several compounds have been shown to modulate TUSC2 expression: - **Sea cucumber peptides (SCP)**: Inhibit NSCLC malignancy by upregulating miR-378a-5p, which targets TUSC2 [2]. - **Coriolus versicolor polysaccharopeptide (PSP)**: Upregulates TUSC2 expression in HL-60 leukemia cells, contributing to apoptosis [13]. - **Metformin and rapamycin**: Protect hearing in Fus1/Tusc2 knockout mice by modulating energy metabolism and mTOR signaling [10]. --- ## 7. Bioinformatic Resources & Database Accessions | **Database** | **Accession / Identifier** | **URL** | |---|---|---| | HGNC | HGNC:12443 | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:12443 | | NCBI Gene | 11334 | https://www.ncbi.nlm.nih.gov/gene/11334 | | Ensembl | ENSG00000115523 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000115523 | | UniProt | O75896 | https://www.uniprot.org/uniprotkb/O75896/entry | | RCSB PDB | N/A (homology models) | https://www.rcsb.org/ | | COSMIC | TUSC2 | https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=TUSC2 | | ClinVar | TUSC2 | https://www.ncbi.nlm.nih.gov/clinvar/?term=TUSC2 | | Gene Ontology (GO) | GO:0006915 (apoptotic process), GO:0005739 (mitochondrion), GO:0019901 (protein kinase binding), GO:0005515 (protein binding) | https://www.ebi.ac.uk/QuickGO/ | | STRING | TUSC2 (O75896) | https://string-db.org/network/9606.ENSP00000284436 | | BioGRID | TUSC2 | https://thebiogrid.org/ | | PharmGKB | TUSC2 | https://www.pharmgkb.org/ | | ClinicalTrials.gov | Quaratusugene ozeplasmid | https://clinicaltrials.gov/ | --- ## Related Clinical & Scientific Guides * [PIK3CA (PI3K Alpha): Helical and Kinase Domain Hotspot Mutations and Isoform-Specific Inhibition](/knowledge/bioinformatics/genes/cancer-genomics/pik3ca-gene-structure-function-pathway) * [ENTPD5 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/cancer-genomics/entpd5-gene-structure-function-pathway) * [PDGFB Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/cancer-genomics/pdgfb-gene-structure-function-pathway) ## References [1] Meraz, I., Majidi, M., Song, R., Wu, S., Gao, L., Meng, F., Ren, C., Xu, Y., Wang, Q., Xi, Y., Wang, J., Jung, S., Shpall, E., & Roth, J. (2025). Abstract 5517: Overcoming sotorasib acquired resistance in KRASG12C mutant NSCLC by TUSC2 gene therapy. *Cancer Research*. https://www.semanticscholar.org/paper/c2726e75620c303fd52cd934da12b07451c0cbfa [2] Meraz, I., Majidi, M., Gao, L., Ren, C., Wu, S., Song, R., Meng, F., Xu, Y., Wang, Q., Xi, Y., Wang, J., Jung, S., Shpall, E., & Roth, J. A. (2024). 384 (PB372): TUSC2 gene therapy in KRASG12C mutant NSCLC overcomes acquired resistance to sotorasib. *European Journal of Cancer*. https://www.semanticscholar.org/paper/e40945af3ae750d4d14d876fb0047cdc1d839ab2 [3] Arrigo, A., Berger, M., & Lo, H. W. (2024). 130 (PB118): Efficacy of Quaratusugene Ozeplasmid TUSC2 Gene Therapy in Glioblastoma. *European Journal of Cancer*. https://www.semanticscholar.org/paper/5f42850eed8a6dd8df5b503b9147084adc7264f6 [4] Meraz, I., Song, R., Wu, S., Xu, Y., Feng, M., Gao, L., Ren, C., Wang, Q., Li, J., Majidi, M., Wang, J., Berger, M. S., & Roth, J. (2026). Abstract 391: TROP2 and PTEN are biomarkers of primary resistance to TUSC2 gene therapy in non-small cell lung cancer (NSCLC). *Cancer Research*. https://www.semanticscholar.org/paper/cdb9517d0cfd00c2ddf3127ce6207b91cc3ade7c [5] Meraz, I., Majidi, M., Shao, R., Gao, L., Feng, M., Chen, H., Ha, M., & Roth, J. (2021). Abstract 1105: Overcoming resistance to osimertinib by TUSC2 gene therapy in EGFR mutant NSCLC. *Experimental and Molecular Therapeutics*. https://www.semanticscholar.org/paper/2a7cce64b0de5713245cf26fe8fb1a7041daecd6 [6] TUSC2 Gene. (2020). *Definitions*. https://www.semanticscholar.org/paper/847ab3c87a148220cb5ccf7eb8507045914873db [7] Meng, J., Majidi, M., Fang, B., Ji, L., Bekele, B. N., Minna, J., & Roth, J. (2013). The Tumor Suppressor Gene TUSC2 (FUS1) Sensitizes NSCLC to the AKT Inhibitor MK2206 in LKB1-dependent Manner. *PLoS ONE*. https://www.semanticscholar.org/paper/20f464582188428ba574783e771f9b6d89ca6dda [8] Tekin, L., Edgünlü, T., & Genç, D. (2024). Immunohistochemical and molecular evaluation of TUSC2 expression in breast cancer. *Molecular Biology Reports*. https://www.semanticscholar.org/paper/c53e25244506ce4be548d1ee210dda26cd79b9fe [9] Banerjee, A., Busette, N., Berger, M. S., Soellner, M., Qin, A., Merajver, S., & Merrill, N. M. (2024). Abstract 351: Quaratusugene ozeplasmid mediated TUSC2 upregulation in EML4-ALK bearing non-small cell lung carcinoma can induce cellular apoptosis. *Cancer Research*. https://www.semanticscholar.org/paper/1f5a8aa7652ba81a9275187054cf6cc64c145c17 [10] Tonello, J., Berger, M. S., Shanker, A., & Ivanova, A. (2024). Abstract 3158: TUSC2 suppresses energy metabolism in lung cancer cells with opposite effects in normal bronchial epithelial cells. *Cancer Research*. https://www.semanticscholar.org/paper/5ec52dd85fa748231608538fa7034065b043f73a [11] Banerjee, A., Busette, N., Cheng, X., Kohagen, K., Bao, L., Lopez-Barcons, L., Berger, M. S., Soellner, M., Qin, A., Merajver, S. D., & Merrill, N. M. (2026). Abstract 469: Quaratusugene ozeplasmid mediated TUSC2 upregulation in EML4-ALK bearing non-small cell lung carcinoma induces apoptosis and is highly effective in preclinical studies. *Cancer Research*. https://www.semanticscholar.org/paper/c20e5939e302060e22ae178670859464f9f981b8 [12] Tan, W. J. T., Santos-Sacchi, J., Tonello, J., Shanker, A., & Ivanova, A. V. (2023). Pharmacological Modulation of Energy and Metabolic Pathways Protects Hearing in the Fus1/Tusc2 Knockout Model of Mitochondrial Dysfunction and Oxidative Stress. *Antioxidants*. https://www.semanticscholar.org/paper/a354c92e678aebeb570b30219872c9a465a4e7f2 [13] Arrigo, A., Regua, A. T., Najjar, M. K., & Lo, H. (2023). Tumor Suppressor Candidate 2 (TUSC2): Discovery, Functions, and Cancer Therapy. *Cancers*. https://www.semanticscholar.org/paper/23500bc07a56147ffcebf8cf9d3f2dd7d6c96ab4 [14] Meraz, I., Majidi, M., Song, R., Meng, F., Gao, L., Wang, Q., Wang, J., Shpall, E. J., Berger, M. S., Kumar, H., & Roth, J. (2023). Abstract A066: TUSC2 immunogene